Cipher Pharmaceuticals Crescita futura
Criteri Future verificati 1/6
Cipher Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 2.1% e 8.2% all'anno. Si prevede che l'EPS crescerà di 0.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 14% in 3 anni.
Informazioni chiave
2.1%
Tasso di crescita degli utili
0.76%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 31.0% |
| Tasso di crescita dei ricavi | 8.2% |
| Rendimento futuro del capitale proprio | 13.98% |
| Copertura analitica | Low |
| Ultimo aggiornamento | 12 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Articolo di analisi • May 14
Investors Shouldn't Be Too Comfortable With Cipher Pharmaceuticals' (TSE:CPH) Earnings
Cipher Pharmaceuticals Inc. ( TSE:CPH ) announced strong profits, but the stock was stagnant. Our analysis suggests...
Aggiornamento della narrazione • May 08
CPH: Higher Cash Returns And Buybacks Will Support Future Upside
Analysts have lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E. These changes support a slightly higher fair value estimate.Aggiornamento della narrazione • Apr 23
CPH: Higher Cash Flow Plans And Buybacks Will Support Future Upside
Analysts have nudged their fair value estimate for Cipher Pharmaceuticals to CA$21 from CA$20, tying the CA$1 price target change to updated assumptions around revenue growth, profit margins and a slightly higher discount rate alongside a lower future P/E. Analyst Commentary Recent research points to a modestly higher fair value for Cipher Pharmaceuticals, with bullish analysts lifting their price target to CA$21 from CA$20.
Aggiornamento della narrazione • Apr 09
CPH: Fair Outlook Will Weigh Natroba Expansion And Acquisition Execution
Analysts have nudged their price target on Cipher Pharmaceuticals up to CA$21 from CA$20, citing updated assumptions that keep fair value broadly steady while fine tuning expectations around growth, margins, and P/E levels. Analyst Commentary The latest price target move to CA$21 from CA$20 signals only a modest reset in expectations, rather than a major shift in conviction.Aggiornamento della narrazione • Mar 26
CPH: Balanced Outlook Will Weigh New Drug Review And Acquisition Execution
Analysts recently lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, reflecting updated assumptions that combine a higher revenue growth outlook with slightly lower profit margin and future P/E expectations. Analyst Commentary The latest price target move to CA$21 suggests that covering analysts are refining their assumptions rather than making a sweeping change in their outlook.Aggiornamento della narrazione • Mar 12
CPH: New Drug Review Will Support Future Upside Potential
Analysts are maintaining their CA$18.60 price target on Cipher Pharmaceuticals. This reflects only small adjustments to their revenue growth and future P/E assumptions, rather than a change in their overall view of the stock.Aggiornamento della narrazione • Feb 26
CPH: New Drug Review And Strong Margins Will Support Further Upside
Analysts kept their CA$18.60 price target on Cipher Pharmaceuticals unchanged, citing only small tweaks to their revenue growth, profit margin and future P/E assumptions that did not materially shift their view of the stock’s value. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad) for the treatment of head lice and scabies, moving the product into the formal review process (Key Developments).Aggiornamento della narrazione • Feb 11
CPH: Higher Margins And New Submission Will Support Future Upside
Analysts have trimmed their price target on Cipher Pharmaceuticals to reflect a more muted revenue growth outlook of 4.30% and a slightly higher discount rate of 6.25%, while still acknowledging a stronger projected profit margin of 39.46% and a broadly similar future P/E of 17.63. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad), targeting head lice and scabies in the Canadian market (Key Developments).Aggiornamento della narrazione • Jan 26
CPH: Share Repurchases Will Drive Future Earnings Power And Upside Potential
Analysts have modestly adjusted their price target for Cipher Pharmaceuticals to reflect slightly updated assumptions around revenue growth of 10.48%, profit margin of 32.39%, and a future P/E of 17.81x. The overall fair value estimate remains at $18.60.Aggiornamento della narrazione • Jan 11
CPH: Share Repurchases Will Support Stronger Future Earnings Profile
Analysts have trimmed their price target on Cipher Pharmaceuticals by aligning slightly lower revenue growth and profit margin assumptions with a modestly higher future P/E. This keeps fair value around $18.60 and reflects a more measured outlook on the company’s earnings profile.Aggiornamento della narrazione • Dec 27
CPH: Share Repurchases And Rising Margins Will Support Stronger Future Earnings
Cipher Pharmaceuticals' analyst price target has been raised from 14.50 dollars to 18.60 dollars, as analysts cite slightly stronger expected revenue growth, modestly higher profit margins, and a richer future earnings multiple as justification for the upward revision. What's in the News Cipher Pharmaceuticals completed the latest tranche of its share repurchase program between July 1, 2025 and September 30, 2025, buying back 141,700 shares, or 0.56 percent of its float, for CAD 2.18 million (Key Developments) Under the buyback announced on May 1, 2025, the company has now repurchased a total of 371,978 shares, representing 1.46 percent of shares outstanding, for aggregate consideration of CAD 5.12 million (Key Developments) Valuation Changes The consensus analyst price target has risen significantly from 14.50 dollars to 18.60 dollars, reflecting a materially higher fair value assessment.Aggiornamento della narrazione • Dec 12
CPH: Share Buybacks Will Support Earnings And Maintain A Balanced Outlook
Analysts have nudged their price target on Cipher Pharmaceuticals higher, from 14.00 dollars to 14.50 dollars, citing stronger expected revenue growth, improved profit margins, and a more attractive forward earnings multiple despite a slightly higher discount rate. What's in the News Cipher Pharmaceuticals repurchased 141,700 shares between July 1 and September 30, 2025, totaling CAD 2.18 million and representing 0.56% of outstanding shares (company buyback update).Articolo di analisi • Nov 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...Articolo di analisi • Oct 10
These 4 Measures Indicate That Cipher Pharmaceuticals (TSE:CPH) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Aggiornamento della narrazione • Sep 05
Expansion Into Canada Will Shape Global Dermatology Success
Cipher Pharmaceuticals' future P/E has risen sharply, indicating increased valuation relative to earnings, while the net profit margin is stable, resulting in no change to the consensus analyst price target at CA$17.90. What's in the News Cipher Pharmaceuticals is actively seeking accretive acquisitions and in-licensing opportunities, with a strategic focus on complementary U.S.-based assets and companies.Articolo di analisi • Aug 29
Cipher Pharmaceuticals Inc.'s (TSE:CPH) Shares Climb 27% But Its Business Is Yet to Catch Up
The Cipher Pharmaceuticals Inc. ( TSE:CPH ) share price has done very well over the last month, posting an excellent...Articolo di analisi • May 16
We Think That There Are More Issues For Cipher Pharmaceuticals (TSE:CPH) Than Just Sluggish Earnings
Investors weren't pleased with the recent soft earnings report from Cipher Pharmaceuticals Inc. ( TSE:CPH ). Our...Articolo di analisi • May 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have had a really impressive month, gaining 29% after a shaky period...Articolo di analisi • Apr 28
Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Nuova narrazione • Feb 23
Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence
Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.Articolo di analisi • Dec 13
We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Nov 14
Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think
Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) earnings announcement last week contained some soft numbers, disappointing...Articolo di analisi • Nov 12
With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders won't be pleased to see that the share price has had a very rough...Articolo di analisi • Nov 09
Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...Articolo di analisi • Mar 23
There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have continued their recent momentum with a 26% gain in the last month...Articolo di analisi • Mar 22
Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
The market rallied behind Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) stock, leading do a rise in the share price after...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 65 | 27 | N/A | 40 | 2 |
| 12/31/2027 | 62 | 26 | N/A | 39 | 3 |
| 12/31/2026 | 53 | 22 | 30 | 28 | 4 |
| 3/31/2026 | 51 | 31 | 29 | 30 | N/A |
| 12/31/2025 | 50 | 27 | 30 | 30 | N/A |
| 9/30/2025 | 50 | 17 | 30 | 30 | N/A |
| 6/30/2025 | 48 | 12 | -59 | 21 | N/A |
| 3/31/2025 | 40 | 9 | -59 | 21 | N/A |
| 12/31/2024 | 33 | 12 | -60 | 20 | N/A |
| 9/30/2024 | 26 | 16 | -67 | 13 | N/A |
| 6/30/2024 | 22 | 23 | 17 | 17 | N/A |
| 3/31/2024 | 22 | 23 | 14 | 14 | N/A |
| 12/31/2023 | 21 | 20 | 16 | 16 | N/A |
| 9/30/2023 | 21 | 32 | 15 | 15 | N/A |
| 6/30/2023 | 20 | 28 | 13 | 13 | N/A |
| 3/31/2023 | 20 | 27 | 13 | 13 | N/A |
| 12/31/2022 | 21 | 27 | 11 | 11 | N/A |
| 9/30/2022 | 22 | 10 | 15 | 15 | N/A |
| 6/30/2022 | 21 | 8 | 11 | 11 | N/A |
| 3/31/2022 | 22 | 9 | 11 | 11 | N/A |
| 12/31/2021 | 22 | 8 | 14 | 14 | N/A |
| 9/30/2021 | 22 | 5 | 14 | 14 | N/A |
| 6/30/2021 | 23 | 6 | 12 | 12 | N/A |
| 3/31/2021 | 21 | 3 | 11 | 11 | N/A |
| 12/31/2020 | 22 | 4 | 11 | 12 | N/A |
| 9/30/2020 | 21 | 7 | 7 | 7 | N/A |
| 6/30/2020 | 22 | 3 | 10 | 11 | N/A |
| 3/31/2020 | 23 | 4 | 11 | 12 | N/A |
| 12/31/2019 | 22 | 3 | N/A | 8 | N/A |
| 9/30/2019 | 23 | -1 | N/A | 8 | N/A |
| 6/30/2019 | 22 | 2 | N/A | 6 | N/A |
| 3/31/2019 | 23 | 3 | N/A | 2 | N/A |
| 12/31/2018 | 23 | 1 | N/A | 8 | N/A |
| 9/30/2018 | 28 | 6 | N/A | 13 | N/A |
| 6/30/2018 | 34 | 9 | N/A | 18 | N/A |
| 3/31/2018 | 37 | 11 | N/A | 19 | N/A |
| 12/31/2017 | 40 | 11 | N/A | 13 | N/A |
| 9/30/2017 | 34 | 7 | N/A | 11 | N/A |
| 6/30/2017 | 32 | 5 | N/A | 9 | N/A |
| 3/31/2017 | 31 | 1 | N/A | 10 | N/A |
| 12/31/2016 | 30 | 4 | N/A | 11 | N/A |
| 9/30/2016 | 33 | 6 | N/A | 8 | N/A |
| 6/30/2016 | 34 | 2 | N/A | 7 | N/A |
| 3/31/2016 | 34 | 1 | N/A | 7 | N/A |
| 12/31/2015 | 34 | 2 | N/A | 8 | N/A |
| 9/30/2015 | 32 | 3 | N/A | 12 | N/A |
| 6/30/2015 | 30 | 13 | N/A | 16 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di CPH ( 2.1% all'anno) è inferiore al tasso di risparmio ( 3% ).
Guadagni vs Mercato: Si prevede che gli utili di CPH ( 2.1% all'anno) cresceranno più lentamente rispetto al mercato Canadian ( 10.7% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di CPH cresceranno, ma non in modo significativo.
Ricavi vs Mercato: Si prevede che il fatturato di CPH ( 8.2% all'anno) crescerà più rapidamente del mercato Canadian ( 4.5% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di CPH ( 8.2% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di CPH sarà basso tra 3 anni ( 14 %).
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/20 04:32 |
| Prezzo dell'azione a fine giornata | 2026/05/20 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cipher Pharmaceuticals Inc. è coperta da 8 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Novak | ATB Cormark Historical (Cormark Securities) |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |